Change search
CiteExportLink to record
Permanent link

Direct link
Cite
Citation style
  • apa
  • ieee
  • modern-language-association-8th-edition
  • vancouver
  • Other style
More styles
Language
  • de-DE
  • en-GB
  • en-US
  • fi-FI
  • nn-NO
  • nn-NB
  • sv-SE
  • Other locale
More languages
Output format
  • html
  • text
  • asciidoc
  • rtf
A multicentre, randomised, controlled, open-label pilot study on the feasibility of discontinuation of adalimumab in established patients with rheumatoid arthritis in stable clinical remission
Karolinska Inst, Unit Clin Therapy Res, Inflammatory Dis ClinTRID, Stockholm, Sweden.ORCID iD: 0000-0002-2163-0525
Lund Univ, Dept Clin Sci, Rheumatol, Malmo, Sweden.
Capio Movement, Reumatol, Halmstad, Sweden.
Uppsala University, Disciplinary Domain of Medicine and Pharmacy, Faculty of Medicine, Department of Medical Sciences, Rheumatology.
Show others and affiliations
2016 (English)In: RMD Open, E-ISSN 2056-5933, Vol. 2, article id e000133Article in journal (Refereed) Published
Abstract [en]

Objectives: Treatment with tumour necrosis factor (TNF) blockers, once started as therapy for rheumatoid arthritis (RA), is usually continued indefinitely. The aim of this trial was to assess the possibility of discontinuing treatment with adalimumab (ADA) while maintaining remission in patients with RA with established disease in stable remission on combination therapy with ADA and methotrexate (MTX).

Methods: In a randomised, controlled, open-label pilot study of patients with RA in stable remission treated with ADA+MTX, patients were randomised in a 1:1 ratio to continue with ADA plus MTX (arm AM) or MTX monotherapy (arm M) for 52 weeks. Flare was defined as Disease Activity Score (DAS28) >= 2.6 or a change in DAS28 (Delta DAS28) of >1.2 from baseline at any time. Patients in arm M with a flare restarted ADA. The primary end point was the proportion of patients in remission at week 28.

Results: 31 patients were enrolled in the study and randomised to arm AM (n=16) or arm M (n=15). At 28 weeks, 15/16 patients (94%) and 5/15 patients (33%) in arms AM and M, respectively, were in remission (p=0.001). During the first 28 weeks, 50% (8/16) in the AM arm and 80% (12/15) in the M arm had a flare (p=0.08). The number of patients in the AM and M arms with >1 Delta DAS28 >1.2 during the first 28 weeks was 1/16 (6%) and 8/15 (53%), respectively (p=0.005).

Conclusions: In this study, remission was rarely maintained in patients with long-standing disease who discontinued ADA. Discontinuation may be feasible in only a minority of patients with established RA in stable clinical remission.

Place, publisher, year, edition, pages
BMJ PUBLISHING GROUP , 2016. Vol. 2, article id e000133
National Category
Rheumatology and Autoimmunity
Identifiers
URN: urn:nbn:se:uu:diva-400181DOI: 10.1136/rmdopen-2015-000133ISI: 000443521500021PubMedID: 26819752OAI: oai:DiVA.org:uu-400181DiVA, id: diva2:1380391
Available from: 2019-12-18 Created: 2019-12-18 Last updated: 2019-12-18Bibliographically approved

Open Access in DiVA

fulltext(1118 kB)10 downloads
File information
File name FULLTEXT01.pdfFile size 1118 kBChecksum SHA-512
4e50617a80c6e55ba0bbaed2b015f8ebe77c9f838e33f9736938d326467f9d6a609c5a180c4f156af7e5d1fc779f85ebe94fe794e8f1cf77a1e143534f2f3637
Type fulltextMimetype application/pdf

Other links

Publisher's full textPubMed

Search in DiVA

By author/editor
Chatzidionysiou, KaterinaKnight, AnnLarsson, Per
By organisation
Rheumatology
In the same journal
RMD Open
Rheumatology and Autoimmunity

Search outside of DiVA

GoogleGoogle Scholar
Total: 10 downloads
The number of downloads is the sum of all downloads of full texts. It may include eg previous versions that are now no longer available

doi
pubmed
urn-nbn

Altmetric score

doi
pubmed
urn-nbn
Total: 10 hits
CiteExportLink to record
Permanent link

Direct link
Cite
Citation style
  • apa
  • ieee
  • modern-language-association-8th-edition
  • vancouver
  • Other style
More styles
Language
  • de-DE
  • en-GB
  • en-US
  • fi-FI
  • nn-NO
  • nn-NB
  • sv-SE
  • Other locale
More languages
Output format
  • html
  • text
  • asciidoc
  • rtf